CD274 and neoplasm: Thus, the effect of immune-checkpoint inhibitors (ICIs) may depend on different tumor microenvironment statuses, and targeting metastatic patients through PD-1/PD-L1 inhibition may be an effective therapeutic strategy under this circumstance.